Business Context and Reporting Period
This Form 8-K is a current report filed by Pieris Pharmaceuticals, Inc. (not Palvela Therapeutics, Inc., as noted in the metadata) on May 22, 2017. The filing reports a corporate governance event: the election of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and related compensation arrangements.
Material Changes
The primary material change reported is the appointment of James A. Geraghty as a Class II Director, with a term expiring at the 2019 annual meeting of stockholders. Mr. Geraghty brings over 30 years of experience in the biotechnology sector, including previous roles at Third Rock Ventures, Sanofi, and Genzyme Corporation.
Compensation and Governance Details
- Stock Option Grant: Mr. Geraghty was granted a non-statutory stock option to purchase up to 30,000 shares of common stock.
- Exercise Price: The option exercise price is set at $3.94 per share, based on the closing price on the date of grant.
- Vesting Schedule: The option vests in equal quarterly installments following the date of grant, contingent on continued service.
- Cash Retainer: Mr. Geraghty is entitled to an annual cash retainer of $35,000.
- Indemnification: An indemnification agreement was executed to cover certain expenses, including legal fees, incurred in connection with his service as a director.
Investor Verification Checklist
- Verify the total number of outstanding shares and the dilution impact of the 30,000 new options granted.
- Review the full text of the Director Compensation Policy to understand the standard compensation structure for non-employee directors.
- Confirm the vesting timeline and any potential acceleration clauses in the stock option agreement.
- Check for any subsequent filings regarding Mr. Geraghty's participation in board committees.